Active Comparator: Treatment of Physician’s Choice (TPC)
Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens:
paclitaxel 80 mg/m^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.
nab-Paclitaxel 100 mg/m^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle.
capecitabine at 1000-1250 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle.
Drug: Paclitaxel
Administered intravenously
Other Name: Taxol®
Drug: Nab-paclitaxel
Administered intravenously
Other Name: Abraxane®
Drug: Capecitabine
Administered orally
Other Name: Xeloda®
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
